999.04MMarket Cap-3093P/E (TTM)
9.490High8.515Low2.78MVolume9.250Open9.340Pre Close24.44MTurnover3.11%Turnover RatioLossP/E (Static)115.76MShares13.17052wk High4.44P/B770.54MFloat Cap1.76052wk Low--Dividend TTM89.29MShs Float40.880Historical High--Div YieldTTM10.44%Amplitude1.760Historical Low8.793Avg Price1Lot Size
Arcutis Biotherapeutics Stock Forum
loading...
Is it merely money? Or is it happiness from the knowledge that we have obtained?
loading...
I expect this to do well today based on its good ER results
NEWS
Positive
Q1 2024 net product revenues of $21.6M, a 675% increase from Q1 2023.
ZORYVE cream and foam contributed $15M and $6.5M to revenues respectively.
Significant demand for ZORYVE products with 208,000 cream prescriptions and 46,000 foam prescriptions.
Raised $172.5M from a public offering.
Strategic licensing agreement in Japan with Sato Pharmaceutical.
FDA accepted sNDA for roflumilast cream for atopic dermatitis with a PDUFA date of July 7, 2024.
Ca...
No comment yet